These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 16093464

  • 1. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
    Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ, PaTH Study Investigators.
    N Engl J Med; 2005 Aug 11; 353(6):555-65. PubMed ID: 16093464
    [Abstract] [Full Text] [Related]

  • 2. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators.
    N Engl J Med; 2003 Sep 25; 349(13):1207-15. PubMed ID: 14500804
    [Abstract] [Full Text] [Related]

  • 3. Daily and cyclic parathyroid hormone in women receiving alendronate.
    Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R.
    N Engl J Med; 2005 Aug 11; 353(6):566-75. PubMed ID: 16093465
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M.
    N Engl J Med; 1995 Nov 30; 333(22):1437-43. PubMed ID: 7477143
    [Abstract] [Full Text] [Related]

  • 6. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD, Farahmand P, Schacht E, Rozehnal A.
    Rheumatol Int; 2007 Mar 30; 27(5):425-34. PubMed ID: 17216477
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S, Fukawa T, Kamiya S.
    Clin Calcium; 2007 Dec 30; 17(12):1888-94. PubMed ID: 18057665
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ.
    J Clin Endocrinol Metab; 2000 Jun 30; 85(6):2129-34. PubMed ID: 10852440
    [Abstract] [Full Text] [Related]

  • 10. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
    Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.
    Ann Intern Med; 2002 Dec 03; 137(11):875-83. PubMed ID: 12458987
    [Abstract] [Full Text] [Related]

  • 11. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
    Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM.
    J Clin Endocrinol Metab; 2006 Apr 03; 91(4):1370-5. PubMed ID: 16449339
    [Abstract] [Full Text] [Related]

  • 12. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 03; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun 03; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 15. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis.
    Miller PD.
    N Engl J Med; 2004 Jan 08; 350(2):189-92; author reply 189-92. PubMed ID: 14714279
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
    Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ.
    N Engl J Med; 1998 Feb 19; 338(8):485-92. PubMed ID: 9443925
    [Abstract] [Full Text] [Related]

  • 18. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, FLEX Research Group.
    JAMA; 2006 Dec 27; 296(24):2927-38. PubMed ID: 17190893
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May 27; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
    Greenspan SL, Resnick NM, Parker RA.
    JAMA; 2003 May 21; 289(19):2525-33. PubMed ID: 12759324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.